An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A person who started taking the diabetes drug Mounjaro (tirzepatide) earlier this year reports a big weight drop—from about 210 pounds to 166 pounds—and says they began the medication after a doctor warned they were pre-diabetic and at risk for heart problems. They also take Repatha (a cholesterol drug) for very high triglycerides. The writer says they used to have binge-eating disorder (BED) and that food felt like an addiction; now they worry that their eating addiction may be "transferring" to other behaviors or that they feel disappointed in themselves despite weight loss. Tirzepatide (branded as Mounjaro) is a medicine originally developed to help control blood sugar in people with type 2 diabetes. It works by acting like natural hormones from the gut that tell your brain you're full and slow how fast your stomach empties. The drug has a strong effect on appetite, so it also causes weight loss in many people. Repatha is a different kind of medicine (a cholesterol-lowering drug) and isn't the focus here; the story is about how changes in appetite and weight interact with past disordered eating. What this report actually shows is a single person's experience: big weight loss after starting tirzepatide and concerns about managing a past addiction-like relationship with food. That is anecdote, not a controlled study. Clinical trials of tirzepatide have shown substantial average weight loss in groups of people, and other reports have noted that appetite suppression can change eating patterns. But one person’s feelings about recovery and possible "addiction transfer"—where a person replaces one compulsive behavior with another—is not proof that the drug causes that problem generally. It is a valuable personal signal that deserves attention, but it doesn't tell us how common this experience is or whether the drug directly causes it. Why this matters: many people with obesity or pre-diabetes also have histories of disordered eating. A medicine that strongly reduces appetite can help with weight and metabolic risk, but it also changes how people relate to food. For someone recovering from binge-eating, that change can be emotionally complicated. Clinicians and patients should be aware that medical weight loss can intersect with mental-health recovery, and a coordinated plan—medical, nutritional, and psychological—can help manage both physical risks and emotional well-being. Caveats and risks: tirzepatide can cause side effects like nausea, diarrhea, and stomach upset, and it needs medical supervision. It’s not approved specifically as a cure for disordered eating, and people with active eating disorders should discuss treatment carefully with their medical and mental-health providers. There’s also limited evidence about long-term effects on eating behaviors and mental health after starting these drugs. If someone notices new compulsive behaviors, worsening mood, or relapse of disordered eating, they should contact their clinician or therapist promptly. Bottom line: the person’s weight loss on tirzepatide is real and medically meaningful, but their concern about “addiction transfer” is a personal warning that deserves careful clinical and psychological follow-up rather than assuming the drug is to blame.
Source: r/Mounjaro